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Abstract
Osteoporosis is a severe condition in postmenopausal women and a common cause of fracture.
Osteoporosis is a complex disease with a strong genetic impact, but susceptibility is determined by
many genes with modest effects and environmental factors. Only a handful of genes consistently
associated with osteoporosis have been identified so far.
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Inflammation affects bone metabolism by interfering with the interplay between bone resorption
and formation, and many inflammatory mediators are involved in natural bone remodeling. The
cytokine macrophage migration inhibitory factor (MIF) has been shown to affect bone density in
rodents, and polymorphisms in the human MIF promoter are associated with inflammatory
disorders such as rheumatoid arthritis. We investigated the association of polymorphisms in the
MIF gene with bone mineral density (BMD) and bone loss in 1002 elderly women using MIF
promoter polymorphisms MIF-CATT5-8 and rs755622(G/C) located -794 and -173 bp upstream of
the transcriptional start site. Bone loss was estimated both by the change in BMD over 5 years and
by the levels of bone resorption markers in serum measured at four occasions during a 5 year
period.
The MIF-CATT7/rs755622(C) haplotype was associated with increased rate of bone loss during 5
years at the femoral neck (p<0.05) and total hip (p<0.05). In addition, the MIF-CATT7/
rs755622(C) haplotype carriers had higher levels of the bone turnover marker serum C-terminal
cross-linking telopeptide of type I collagen (S-CTX-I, p<0.01) during the 5 year follow-up period.
There was no association between MIF-CATT7/rs755622(C) and baseline BMD at femoral neck,
total hip or lumbar spine.
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We conclude that MIF promoter polymorphisms have modest effects on bone remodeling and are
associated with the rate of bone loss in elderly women.
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Introduction
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Osteoporosis is a common disease, affecting one in three women during the course of their
lifetime. It is characterized by reduced bone mass, micro-architectural deterioration of bone
tissue and an increased risk of fractures; herein lies the clinical importance of the disease
[1]. Osteoporosis is a complex disease with both genetic and environmental risk factors.
Many genes are believed to contribute to the genetically conferred risk, with each gene
having only a moderate effect. There are also gene-gene interactions and interaction between
genes and the environment. Clinical risk factors will vary between individuals, thus each
osteoporotic patient likely has a unique combination of genetic and environmental risk
factors. It is known that some genes are specific to bone mineral density (BMD) while
others may be shared not only with other bone related phenotypes, but also with other
complex diseases such as obesity and diabetes [2]. The influence of genetic factors on
osteoporosis risk is significant, affecting all aspects of the osteoporotic phenotype; e.g.
BMD, bone quality, structure and strength. Twin- and family studies have shown that 60–
80% of the population variance in BMD, which is the strongest clinical predictor of fracture
risk, is genetically determined [3].
Inflammation can affect the balance between bone formation and resorption and patients
with chronic inflammatory diseases seem to be at higher risk of developing osteopenia [4].
The interplay between the immune system and bone metabolism, or ‘osteoimmunology’,
includes molecular and cellular interactions between osteoblasts, osteoclasts, lymphocytes
and the monocyte-macrophage lineage [5]. The link between inflammation and bone
turnover appears to depend mainly on the production of cytokines. As estrogen levels
decline at menopause, there is an increase in the production of pro-inflammatory cytokines
that may contribute to increased osteoclast activity and subsequent loss of bone density.
However, cytokines have dual roles in bone homeostasis, with different effects depending
on the type of immune response [5-7].
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Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine mainly
produced by immune cells (including T-cells, macrophages and monocytes), and it plays
important roles in both the innate and acquired immune response. For instance, MIF
contributes to the pathogenesis of acute, chronic and autoimmune inflammatory disorders
and it counterbalances the immunosuppressive effects of glucocorticoids [8]. MIF also has
been identified as an upstream regulator of TNFα, which has important effects in bone
resorption [9]. In murine models, MIF has been shown to be highly expressed in osteoblasts
and to induce expression of matrix metalloproteinases-9 and -13 in these cells [10].
Transgenic mice overexpressing MIF develop osteoporosis [11] while MIF-deficient mice
are resistant to ovariectomy-induced bone loss [12]. The expression of MIF is also increased
during fracture healing in rats [13]. Several experimental studies thus show that local MIF
levels influence or reflect the extent of bone remodeling.
In human subjects, increased levels of MIF have been found in the joints of juvenile and
adult rheumatoid arthritis patients [14-16], and polymorphisms in the promoter region of
MIF have been shown to affect the level of gene transcription and to be associated to the
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pathogenesis of rheumatoid arthritis and several other inflammatory diseases [17-19]. The
rs755622(C) allele located -173 bp upstream of MIF transcriptional start site creates an
activator protein-4 response element that is associated with increased expression of MIF and
poor clinical outcome of juvenile idiopathic arthritis [20-22]. MIF-CATT5-8 is a
tetranucleotide repeat polymorphism located -794 bp upstream of mRNA transcriptional
start site and higher number of repeats is associated with increased expression of MIF and
disease severity in rheumatoid arthritis [17].
There are several reports on disease association for the MIF-CATT7/rs755622(C) haplotype
including inflammatory polyarthritis [23], scleroderma [24], atopy [25], prostate cancer [26],
psoriasis [27], asthma [28], and systemic lupus erythematosus [29]. The risk haplotype MIFCATT7/rs755622(C) was also associated with increased MIF expression in inflammatory
polyarthritis [23], while the low-expression allele MIF-CATT5 was associated to mild
asthma [28], arguing for functional effects of these, or closely linked, promoter
polymorphisms. There is thus experimental evidence of an important role for MIF in bone
turnover and polymorphisms in the promoter region of MIF have both been reported to
affect transcription and be associated to inflammatory diseases. The aim of this study was to
evaluate the effect of MIF promoter polymorphisms with regard to BMD and the rate of
bone resorption.
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The present study was performed in a population-based cohort of 1002 postmenopausal
women aged 75 years at inclusion with information collected at the baseline visit and at the
1, 3, and 5-year follow-up visits. This is the first study to address genetic association of MIF
to osteoporosis.

Materials and methods
Study subjects
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The Malmö Osteoporotic Prospective Risk Assessment (OPRA) cohort is a populationbased cohort of Caucasian women aged 75 years who were randomly selected from the
Malmö city files between 1995 and 1999. No exclusion criteria were applied. A total of
1604 women were invited, 1044 (65%) chose to attend at baseline and 753 women returned
for the 5 year follow-up visit. Phenotype data reported in this study include BMD at the
lumbar spine, femoral neck and total hip at baseline and at the 5 year follow up visit. In
addition, bone resorption markers were measured in serum at baseline and at the 1-, 3-, and
5-year follow-up visits. Information on medication, smoking and illness was collected by a
questionnaire. The data reported in this analysis is based on women for whom MIF genotype
data was available, corresponding to 1002 women at baseline and 753 women at 5-year
follow up. Of the 1002 women at baseline, 138 were smokers, 198 were former smokers, 66
had diabetes and 115 were using estrogen (not including low-potency estriol) or
bisphosphonates during the 5 year follow-up period. Clinical characteristics of the women
attending the baseline visit are shown in Table 1.
Participants gave informed consent and the Lund University Ethics Committee approved the
study. This study was performed according to the principles of the Helsinki declaration.
Genotyping
Total genomic DNA was isolated from blood using the QIAamp 96 DNA blood kit (Qiagen,
Valencia, CA, USA) according to the manufacturer's instructions. Genotyping of rs755622
(MIF-173G/C) was performed using Taqman SNP genotyping Assay (partnumber
C_2213785_10, Applied Biosystems, Foster City, CA, USA). PCR was conducted in a Dual
384-well GeneAmp PCR system 9700 (Applied Biosystems). After PCR amplification an
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endpoint plate read on ABI 7900HT (Appied Biosystems) using the SDS2.2.2 software, was
performed. The success rate of genotyping of rs755622 was 99.4%.
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The microsatellite MIF-CATT5-8 (-794[CATT]5-8) was genotyped by PCR from 20ng DNA
for a 10 μl reaction using primers as follows: 5′TTG CAC CTA TCA GAG ACC-3′as a
forward primer with 5′end labeled with 6-FAM and 5′-TCC ACT AAT GGT AAA CTC
G-3′as a reverse primer. PCR was conducted in a 96-well GeneAmp PCR System 2700
(Applied Biosystems) and comprised 40 cycles 95°C 1 min, 54°C 1 min and 72°C 45 s
followed by one cycle 72°C 7 min. Amplification was confirmed by 3% agarose gel
electrophoresis before denaturated products were run with an internal sizing standard
GeneScan™-400HD (Applied Biosystems) on a ABI Prism 3130 genetic Analyzer (Applied
Biosystems). After the capillary electrophoresis, the alleles of MIF-CATT5-8 were identified
using Genemapper 3.0 software (Applied Biosystems). The success rate of genotyping of
MIF-CATT5-8 was 99.7%.
Bone density
The areal BMD at the femoral neck, total hip and lumbar spine (L2-L4) was measured by
dual-energy x-ray absorptiometry (DXA) (Lunar DPX-L® Madison, USA). Analyses of
scans were made with software versions 1.33 and 1.35 at baseline and 4.7b at 5 years. The
total hip scans were all analyzed with version 4.7b.
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The rate of bone loss represents the annual change in BMD (%) between the scan at baseline
(BMDBL) and the 5 year follow-up (BMD5Y), and was calculated as [(BMD5Y-BMDBL)/
BMDBL/years between scans × 100].
The rate of bone loss at the lumbar spine is not reported since previously in this cohort we
showed that BMD increased, likely due to the presence of osteophytes, degenerative
changes and compressive fractures common in women of this age [30].
Bone resorption markers
Serum C-terminal cross-linking telopeptide of type I collagen (S-CTX-I) and serum tartrateresistant acid phosphatase 5b (S-TRACP5b) were analyzed. Non-fasting blood samples were
collected between 08.00 and 13.00 and centrifuged within 2 hours after phlebotomy to
isolate plasma. Samples were stored at -80°C. Storage times were up to 3.6 years apart since
participants entered the study at 75 years of age but at different timepoints. This difference
in storage time had only minor effects on the measures of bone resorption markers [30].
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S-TRACP5b was determined with BoneTRAP® assay (SBA Sciences/Immunodiagnostic
Systems IDS Inc., Bolton, UK) and S-CTX-I was determined with Elecsys β-CrossLaps
immunoassay (Roche Diagnostics, Indianapolis, IN).
In the analyses of bone resorption markers, subjects that had received estrogen or
bisphosphonate treatment anytime during the 5 year follow-up period were excluded since
these medications have been shown to decrease S-CTX-I levels [31, 32]. Longitudinal
measures of bone resorption markers at baseline and at the 1-, 3-, and 5-year follow-up visits
were used. Longitudinal data from the four occasions was available from 537 subjects for STRACP5b and from 519 subjects for S-CTX-I. The log transformed mean value for the four
visits were used for analysis. To compare women with high and low levels of bone turnover,
subjects were classified as having consistently high (or consistently low) values of S-CTX-I
or S-TRACP5b if they appeared in the higher (or lower) tertile at three or all four of the time
points studied. All other were classified into the intermediate group [33].
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Statistics
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Deviation from Hardy-Weinberg equilibrium was calculated by the chi-square test. Markermarker association between MIF-CATT5-8 and rs755622 was analyzed with the EHplus
software [34] based on genotype data from the OPRA cohort. Haplotypes were estimated by
PHASE version 2.02 [35]. Only individuals with a haplotype estimate >80% were used in
haplotype analyses (n=1001). SPSS for Windows 17.0 (SPSS Inc., Chicago, IL) was used
for statistical analysis. The paired t-test was used to test for change in BMD and weight
between baseline and the 5 year follow-up visit. Linear regression was used to identify
confounding factors. ANOVA was used to determine associations between MIF genotypes,
BMD and rate of bone loss. Bone resorption marker values were log-transformed prior to
analysis due to non-normal distribution. For MIF association analyses to levels of bone
resorption markers, the t-test was used for comparing mean S-CTX-I and S-TRACP5b
values, and the Pearson Chi-Square test was used for resorption marker analyses between
consistently high and low expression of S-CTX-I or S-TRACP5b.

Results
Genotype frequencies
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There was no deviation from Hardy-Weinberg equilibrium for SNP rs755622 (p=0.78) or
the microsatellite MIF-CATT5-8 (p=0.30). The allele- and genotype frequencies for
rs755622 and MIF-CATT5-8 are shown in Table 2 and are similar to those reported in other
Caucasian populations [36]. The most frequent MIF-CATT5-8 allele was 6 repeats (61%),
while 8 repeats was rare (0.1%). The markers were significantly associated (χ2=743,
p<0.000001), and are thus in linkage disequilibrium. Three haplotypes (MIF-CATT5/
rs755622(G), MIF-CATT6/rs755622(G), MIF-CATT7/rs755622(C)) accounted for 96% of
the estimated haplotypes (Table 3).
Association to BMD
MIF-CATT5-8, rs755622 alleles or constructed haplotypes were not associated to BMD at
the femoral neck, total hip or lumbar spine in the 75-year old women at baseline or at the 5
year follow-up visit. Correction for confounders identified by linear regression was made for
weight (at baseline), diabetes, smoking status and current use of estrogen or bisphosphonates
at the baseline visit and for weight (at 5 years) at the 5 year follow-up visit.
Association to rate of bone loss
There was a significant decrease in both body weight and in BMD at the femoral neck and
total hip between baseline and the 5 year follow-up visit (p<0.001).
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The mean annual rate of bone loss between baseline and the 5-year follow-up visit was a 1.5% change in BMD for femoral neck and -1.2% for total hip (Table 1). Body weight at the
baseline visit was used as covariate for analyses of rate of bone loss. Diabetes, smoking
status and use of estrogen or bisphosphonates were not significant confounders for rate of
bone loss.
The MIF-CATT7/rs755622(C) haplotype, previously identified as being associated with
increased expression of MIF [23], was associated to rate of bone loss both at the femoral
neck (p=0.04) and total hip (p=0.038, Table 4).
The mean rate of bone loss for individuals carrying the MIF-CATT7/rs755622(C) haplotype
was 28% higher for femoral neck and 29% higher for total hip compared to the mean rate of
bone loss for non-carriers of the haplotype (Table 4). There was no association between MIF
haplotype and the 5-year change in body weight.
Bone. Author manuscript; available in PMC 2011 June 30.
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Association to bone resorption markers
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The mean values for S-CTX-I and S-TRACP5b measures at baseline, 1, 3, and 5 years were
highly correlated (Pearson correlation 0.52, p<0.001). Of the 105 individuals that were
classified as having consistently high or low levels of S-CTX-I and S-TRACP5b, 41% were
high and 48% were low for both markers.
Carriage of the MIF-CATT7/rs755622(C) haplotype was compared between individuals with
consistently high and consistently low levels of bone resorption markers S-CTX-I or STRACP5b at baseline, 1-, 3-, and 5-year follow-up. For subjects with inferred MIF
haplotype data, the number of consistently high/low were 91/108 for S-TRACP5b and
120/117 for S-CTX-I. There were more MIF-CATT7/rs755622(C) carriers in the groups
with consistently high levels of bone resorption markers than in the groups with consistently
low levels (S-CTX-I; p=0.01, S-TRACP5b; p=0.06, Table 5).
MIF-CATT7/rs755622(C) haplotype carriers also had significantly higher mean S-CTX-I
levels (5.79 nM) than non-carriers (5.67 nM, p=0.005). There was no significant difference
in means for S-TRACP5b (1.32 U/L vs. 1.28 U/L, p=0.12).

Discussion
NIH-PA Author Manuscript

Reports from rodent experiments including transgenic mice argue for a strong effect of MIF
on bone metabolism, particularly after ovariectomy and during fracture healing [11-13].
Numerous studies have identified functional effects for polymorphisms in the MIF promoter
region that affect the level of gene expression and are associated with susceptibility or
severity of diseases with an inflammatory component [17, 18, 20, 37]. Combining these
findings creates an argument for studying the potential association of MIF promoter
polymorphisms with human osteoporosis.
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The MIF promoter polymorphisms MIF-CATT5-8 and rs755622 were not observed to be
associated with BMD at the femoral neck, total hip or lumbar spine in 75-year old women.
The lack of association to baseline BMD suggests that other factors such as diet, medication
and other genetic factors have more pronounced effects on BMD in women of this age. In
contrast, there was a moderate association of the MIF-CATT7/rs755622(C) haplotype to
bone loss during the 5 year follow-up period (between age 75 and 80). Bone loss was
assessed both by annual change in BMD, i.e. rate of bone loss, and by the levels of the bone
resorption markers S-CTX-I and S-TRACP5b. Mean values of S-CTX-I from measures at
baseline, 1-, 3-, and 5-year follow-up were significantly higher in MIF-CATT7/rs755622(C)
haplotype carriers, but since bone turnover markers vary over time we also identified
individuals with consistently high or low levels of these markers at the four occasions. The
strategy to classify individuals into groups with consistently high and low levels of bone
resorption markers was recently shown to correlate well with the rate of bone loss and
osteoporosis risk [33]. This method results in a more robust classification by minimizing the
effects of variation ensuing from different measurement days (years) and from the intraindividual variation within each subject (seasonal, diet, exercise).
For both S-TRACP5b and S-CTX-I there were more MIF-CATT7/rs755622(C) haplotype
carriers, higher mean levels of the respective bone resorption markers and higher rate of
bone loss in the “consistently high” compared to “consistently low” group.
Bone turnover markers can be used as predictive tools for women at high risk of fracture
[38-40]. S-CTX-I is elevated upon increased degradation of bone collagen while TRACP5b
is an enzyme expressed by osteoclasts, thus S-TRACP5b is a measure of both osteoclast
number and activity [41, 42]. Recent data from the OPRA cohort suggests that elevated
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levels of S-TRACP5b and S-CTX-I are associated with increased fracture risk for up to a
decade in the elderly women [43]. Genetic association to levels of bone resorption markers
and bone loss as reported here for MIF promoter polymorphisms are thus clinically relevant.
MIF could also be the target for pharmacological intervention. Several MIF inhibitors have
been developed [44] but their potential clinical use in osteoporosis can currently only be
speculated upon and requires more knowledge on the biological function of MIF in relation
to bone. Sufficiently detailed information on duration and dosage of anti-inflammatory
drugs was not available in the OPRA cohort and precluded investigation of interactions in
relation to MIF haplotype.
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Results obtained from a transgenic mouse model over expressing MIF and from a rat
fracture model have pointed to a role for MIF in promoting bone resorption [11, 13]. On the
other hand, studies in MIF-deficient or knock-out mice of different sexes have generated
somewhat conflicting results. One study reported that mif-/- females were resistant to
ovariectomy induced bone loss [12] while another study reported reduced trabecular bone
volume in males, but with no changes in the number of osteoclast or osteoblasts [45]. MIF
clearly plays a complex role in bone remodeling. Ex vivo cultures of bone marrow cells from
mif-/- male mice have shown evidence of enhanced osteoclast formation while in vitro
studies suggest that exogenous MIF is a potent inhibitor of osteoclast formation at a late
stage of the differentiation/fusion process [45]. Accordingly, the observations from mice
over-expressing MIF and from mice in which the mif gene has been deleted are difficult to
reconcile. Pertinent to the difficulties in comparing osteoclast formation in dissimilar in vitro
and in vivo systems is the observation that osteoclast formation in bone marrow cultures is
not necessarily representative of all skeletal sites. Furthermore, differences in the local
microenvironment, MIF concentrations and cell-to-cell contacts may complicate
comparisons between ex vivo and in vivo results. For example, a recent study found that
although retinol is associated with decreased bone mass and increased fractures in humans,
and to increased periosteal bone resorption (both in vivo and bone organ cultures) retinol is
also a potent inhibitor of osteoclast formation in bone marrow and spleen cell cultures [46].
These and other observations [47, 48] indicate the existence of local differences in the
regulation of bone resorption which must be taken into consideration when interpreting
results from diverse model systems.
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One of the bone resorption markers used in the present study, S-TRACP-5b is a marker for
osteoclast number and bone resorption. There was suggestive evidence (p=0.06) for
increased S-TRACP-5b levels in carriers of the MIF-CATT7/rs755622(C) haplotype which
could reflect increased number of osteoclasts. Another possibility, suggested from the results
from MIF-transgenic mice, could be that in vivo the inhibitory effect on osteoclastogenesis
is overridden by MIF-induced TNFα expression, which has stimulatory effects on
osteoclasts [9].
In either case the observations in the present study suggest that elevated MIF levels are
associated with increased bone resorption in post-menopausal women. While the mechanism
is not clear, it may be mediated through the estrogen pathway, since estrogen is known to
inhibit inflammatory responses in humans [49] and strongly inhibits inflammation mediated
MIF production in mice [50]. This being the case, the MIF-CATT7/rs755622(C) haplotype
in conjunction with estrogen depletion may synergistically contribute to bone loss in these
women. Replication in pre-menopausal women or older women taking estrogen replacement
therapy may prove interesting to study.
The finding that the rate of bone loss can itself be predictive of fracture makes it clinically
relevant to study [51, 52]. Our preliminary results suggest that combining information on
MIF haplotype and bone turnover markers may provide additional useful information in the
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prediction of bone loss and fracture risk. The p-values for MIF-CATT7/rs755622(C)
association to rate of bone loss and S-CTX-I are modest (p<0.05, p<0.01) and not corrected
for multiple testing due to the non-independent relationship between resorption markers and
between the skeletal sites studied; nonetheless the result is suggestive of association. The
consistency between the measurements of bone loss (i.e. rate of bone loss and levels of bone
resorption markers) point in the same direction i.e. that MIF-CATT7/rs755622(C) haplotype
increases the extent of bone resorption, leading to bone loss in elderly women.
To the best of our knowledge, the present report is the first study to address the association
between MIF promoter polymorphisms and osteoporosis or bone loss. It was conducted in a
large, well characterized cohort with relevant characteristics for the study of changes in
bone, as the typical osteoporotic, fracture-prone patient is an elderly woman. In addition, we
include data from baseline and three follow-up visits, allowing for the analyses on changes
in bone over time. A limitation of this study was the lack of systemic inflammation markers.
The OPRA cohort studied lacks complete data on the inflammatory status of the participants
such as CRP levels and inflammatory disease. Biochemical measures and more detailed
questionnaires regarding illness would have improved the ability to study MIF promoter
polymorphisms with regard to both bone and inflammation.
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In conclusion, the MIF promoter polymorphisms previously shown to be associated with
increased MIF expression and inflammation are associated with bone loss measured by
change in BMD and levels of bone resorption markers in elderly women, identifying MIF as
a genetic risk factor for osteoporosis.
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Table 1

Clinical characteristics of women in the OPRA cohort

NIH-PA Author Manuscript

Variable

Mean

SD

Min

Max

Age at baseline (years)

75.2

0.1

75.0

75.9

Age at 5-year follow-up (years)

80.2

0.2

79.6

80.9

Weight at baseline (kg)

67.8

11.5

41

110

Weight at 5-year follow-up (kg)

66.2

11.5

34

105

Height at age 20 (cm)

164.1

5.5

145

180

Femoral neck at baseline

0.748

0.130

0.153

1.230

Total hip at baseline

0.849

1.149

0.498

1.416

Lumbar spine at baseline

0.993

0.195

0.518

1.855

Femoral neck at 5-year follow-up

0.713

0.128

0.150

1.480

Total hip at 5-year follow-up

0.800

0.140

0.260

1.390

Lumbar spine at 5-year follow-up

1.009

0.206

0.470

1.790

Femoral neck

-1.476

2.162

-13.89

7.70

Total hip

-1.230

1.868

-10.39

6.33

BMD

(g/cm2)

Rate of bone loss per year

NIH-PA Author Manuscript

Number of individuals (N) for each phenotype: Age at baseline (BL): 1002, Age at 5 years (y): 753, Weight BL: 1002, Weight 5y: 702, Height at
age 20: 958, Femoral neck (FN) BL: 923, Total hip (TH) BL: 902, Lumbar spine (LS) BL: 945, FN 5y: 678, TH 5y: 676, LS 5y: 693, Rate of bone
loss (RBL) FN: 655, RBL TH: 638
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469
1226
304
3

5
6
7
8

361

C

MIF-CATT5-8

1635

G

rs755622

N

Allele

MIF polymorphism

0.001

0.15

0.61

0.23

0.18

0.82

Frequency

998

Total

2
388
173
1
24
1001

66
67
68
77
Total

83

276

58

57

56

54

34

55

293

CC

671

N

GC

GG

Genotype

2.4

0.1

17.3

38.8

0.2

8.3

27.6

5.4

3.4

29.4

67.2

%

NIH-PA Author Manuscript

MIF allele and genotype frequencies in the OPRA cohort
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Table 3

Estimated MIF haplotype frequencies (N=1002)
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MIF allele

MIF haplotype

CATT5–8 repeats

rs755622

Frequency (%)

5

G

23.3

5

C

0.2

6

G

58.1

6

C

3.0

7

G

0.5

7

C

14.8

8

C

0.2

NIH-PA Author Manuscript
NIH-PA Author Manuscript
Bone. Author manuscript; available in PMC 2011 June 30.

Swanberg et al.

Page 15

Table 4

NIH-PA Author Manuscript

Mean annual rate of bone loss (RBL) for carriers and non-carriers of the MIF-CATT7/rs755622(C) haplotype
MIF-CATT7/rs755622(C)
Non-carriers

Carriers

Femoral neck

n= 482

n= 173

Mean RBL

-1.37

-1.76

SD

2.09

2.34

Range

-8.54 to 7.7

-13.89 to 7.27

Total hip

n= 468

n =170

Mean RBL

-1.14

-1.47

SD

1.86

1.87

Range

-7.15 to 6.33

-10.39 to 6.13

a
p-value

0.04

0.04

a

Univariate GLM-ANOVA

NIH-PA Author Manuscript
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Table 5

NIH-PA Author Manuscript

Relative expression of S-CTX-I and S-TRACP5b in carriers and non-carriers of the MIF-CATT7/rs755622(C)
haplotype
MIF-CATT7/ rs755622(C)
Non-carriers (%)

Carriers (%)

a
P-value

Consistently high

75 (62.5)

45 (37.5)

0.01

Consistently low

90 (76.9)

27 (23.1)

Consistently high

62 (68.1)

29 (31.9)

Consistently low

85 (78.7)

23 (21.3)

S-CTX-I

S-TRACP5b
0.06

a

Chi square test
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